Trials / Completed
CompletedNCT00637091
Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
A Phase II Trial of Cetuximab Plus Irinotecan as a 2nd-line Treatment in Patients With Metastatic Colorectal Cancer After Failure to Irinotecan That Express Wild-type KRAS With and Without Detectable EGFR Expression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the response rate of cetuximab plus irinotecan every 2 weeks in patients harboring wild-type KRAS with and without detectable EGFR-expressing metastatic CRC after failure to irinotecan in an exploratory manner.
Detailed description
Twenty patients with positive-EGFR results and 20 patients with negative-EGFR results will be accrued in this study. All patients should have wild-type KRAS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab, irinotecan | cetuximab, irinotecan |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-09-01
- Completion
- 2011-09-01
- First posted
- 2008-03-17
- Last updated
- 2021-01-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00637091. Inclusion in this directory is not an endorsement.